CNTA
Centessa Pharmaceuticals plc NASDAQ$39.57
Mkt Cap $5.4B
52w Low $10.95
97.6% of range
52w High $40.26
50d MA $32.29
200d MA $24.92
P/E (TTM)
-27.1x
EV/EBITDA
-16.1x
P/B
10.2x
Debt/Equity
0.0x
ROE
-37.5%
P/FCF
-17.5x
RSI (14)
—
ATR (14)
—
Beta
1.26
50d MA
$32.29
200d MA
$24.92
Avg Volume
2.6M
About
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which i…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.37 | -0.48 | -29.2% | 39.72 | +0.1% | +0.4% | -0.1% | -0.1% | -0.4% | -0.5% | -0.8% | — |
| Nov 5, 2025 | AMC | -0.39 | -0.41 | -5.1% | 22.52 | -1.5% | +1.4% | -1.8% | -0.8% | +0.1% | +18.6% | +32.8% | — |
| Aug 12, 2025 | AMC | -0.35 | -0.38 | -8.6% | 17.11 | +0.5% | +0.2% | +3.1% | +5.5% | +2.8% | +1.3% | +32.5% | — |
| May 14, 2025 | AMC | -0.35 | -0.20 | +42.9% | 12.27 | -0.5% | +2.6% | +2.0% | -0.1% | +7.6% | +4.5% | +0.9% | — |
| Mar 24, 2025 | AMC | -0.38 | -0.34 | +10.5% | 16.63 | -0.6% | -4.9% | -12.6% | -12.7% | -12.3% | -13.5% | -21.6% | — |
| Nov 12, 2024 | AMC | -0.42 | -0.37 | +11.9% | 17.00 | +3.4% | +6.4% | +2.9% | -5.9% | -5.3% | -1.0% | -0.8% | — |
| Aug 13, 2024 | AMC | -0.38 | -0.40 | -5.3% | 11.01 | +3.1% | +14.4% | +18.9% | +13.5% | +11.8% | +9.2% | +37.1% | — |
| May 13, 2024 | AMC | -0.41 | -0.38 | +7.3% | 8.83 | -0.2% | +2.4% | -0.5% | +1.4% | +0.5% | -1.2% | +9.9% | — |
| Mar 28, 2024 | AMC | -0.44 | -0.38 | +13.6% | 11.30 | +1.5% | -1.9% | +0.3% | -4.2% | -8.2% | -4.9% | -17.8% | — |
| Nov 13, 2023 | AMC | -0.46 | -0.40 | +13.0% | 6.24 | +3.8% | +6.2% | +15.5% | +11.9% | +12.8% | +9.6% | +6.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $39.66 | $39.60 | -0.2% | -0.4% | -0.4% | -0.5% | -0.6% | -0.5% |
| Apr 2 | Guggenheim | Downgrade | Buy → Neutral | — | $39.86 | $39.70 | -0.4% | -0.4% | -0.5% | -0.8% | -0.8% | -0.3% |
| Apr 1 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $39.72 | $39.75 | +0.1% | +0.4% | -0.1% | -0.1% | -0.4% | -0.5% |
| Mar 31 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $27.58 | $40.03 | +45.1% | +44.0% | +44.5% | +43.9% | +43.8% | +43.4% |
| Mar 31 | Needham | Downgrade | Buy → Hold | — | $27.58 | $40.03 | +45.1% | +44.0% | +44.5% | +43.9% | +43.8% | +43.4% |
| Jan 29 | Truist | Maintains | Buy → Buy | — | $25.24 | $25.39 | +0.6% | -1.4% | -2.7% | -0.2% | +1.0% | -1.0% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $22.69 | $22.75 | +0.3% | -2.8% | -1.2% | -3.0% | -2.1% | -2.6% |
| Jan 2 | Chardan Capital | Maintains | Buy → Buy | — | $25.01 | $24.88 | -0.5% | -5.3% | -8.0% | -9.3% | -9.3% | -11.8% |
| Dec 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $28.60 | $29.11 | +1.8% | +3.4% | -5.0% | -7.3% | -8.6% | -10.1% |
| Dec 1 | B. Riley Securities | Maintains | Buy → Buy | — | $29.03 | $29.63 | +2.1% | -1.9% | -1.8% | +0.1% | +1.8% | +3.0% |
Recent Filings
8-K
Eli Lilly and Company -- 8-K Filing
Eli Lilly's strong Q1 2026 results—revenue up 56% to $19.8B and EPS up 170% to $8.26—combined with raised full-year guidance demonstrate robust momentum despite Mounjaro/Zepbound price pressure, signaling sustained growth.
Apr 30
8-K
Centessa Pharmaceuticals plc -- 8-K Filing
Centessa Pharmaceuticals executed a separation agreement with extended benefits and a general release of claims, effective after a seven-business-day revocation period.
Feb 13
Data updated apr 26, 2026 10:13am
· Source: massive.com